Amanda Cano (Spain)
Ace Alzheimer Center Barcelona
Clinical Research - Biomarkers' Unit
Dr. Cano currently holds a postdoctoral researcher position in the clinical research department of Ace Alzheimer Center Barcelona. Previously, she was an adjunct professor of Physical Chemistry at the University of Barcelona. She graduated from Pharmacy at the University of Salamanca in 2013 and received her master’s degree in 2014 from the University of Barcelona. In 2018, she finished her Ph.D. studies on nanomedicine and neuropharmacology, and obtained the doctoral degree from the University of Barcelona. She carried out several international research stays at the University of Trás-os-Montes and Alto Douro in Portugal, the University College of London in the United Kingdom, and the University of Modena and Reggio Emilia in Italy. She is a member of the Consolidated Research Group of the Generalitat de Catalunya “Nanostructured systems for the controlled release of drugs” (2017SGR-1477), Institute of Nanoscience and Nanotechnology (IN2UB), and Center for Biomedical Research in Neurodegenerative Diseases Network (CIBERNED). She has participated in several competitive European and national projects and published more than 40 scientific papers. She is in charge of the molecular biology unit of her center and her studies are related to the clinical evaluation of early biomarkers of Alzheimer's disease.

Presenter of 1 Presentation

 Conference Calendar

DIAGNOSTIC POTENTIAL OF BIOMARKERS LOADED IN PLASMA-DERIVED EXOSOMES IN A COHORT OF EARLY-ONSET MILD COGNITIVE IMPAIRMENT: THE BIOFACE STUDY.

Session Name
1650 - FLUID BIOMARKERS 5 (ID 81)
Session Type
SYMPOSIUM
Date
Sat, 19.03.2022
Session Time
02:45 PM - 04:45 PM
Room
ONSITE: 114
Lecture Time
04:30 PM - 04:45 PM
Presenter

Abstract

Aims

Currently, molecular diagnosis of Alzheimer`s disease (AD) is based on cerebrospinal fluid (CSF) biomarkers. It is performed once first symptoms appear and neuronal damage is already irreversible. Therefore, an accurate early diagnosis is one of the great challenges in the AD field. Growing interest has been focused in plasma-derived exosomes (pEXO), which have shown to reflect the molecular alterations occurring at a central level in the different stages of AD. Thus, the aim of this project is to evaluate the diagnostic potential of pEXOs through the analysis of their biomarkers´ cargo in an early-onset mild cognitive impairment (EOMCI) cohort.

Methods

Data from 80 participants with EOMCI were analyzed. pEXOs were isolated by using ultracentrifugation method. Concentration of 184 biomarkers in of CSF, plasma and pEXOs were analyzed by using ProSeek® multiplex immunoassay of Olink Proteomics. Neuroimaging were performed by brain MRI. CSF AD biomarkers were used to determine the Aβ status of the participants.

Results

pEXOS from EOMCI Aβ+ participants showed an increased total protein amount compared to EOMCI Aβ-. Several biomarkers showed different levels in CSF and pEXOs samples of EOMCI Aβ+ vs EOMCI Aβ-, but not in plasma. Several biomarker of EOMCI Aβ+ pEXOs samples were significantly correlated with some brain areas and p-Tau levels, but not in EOMCI Aβ-. Further studies are needed to validate these results.

Conclusions

pEXOs could have the potential to be a suitable tool for the early diagnosis of AD.Conclusion: pEXOs could have the potential to be a suitable tool for the early diagnosis of AD.

Hide